Videos

Delphi panel reveals how NPs and PAs can talk about long-acting injectables earlier in schizophrenia, boosting adherence and cutting relapse.

Let's take a look at the next generation of pharmacotherapies for mood and anxiety disorders.

Alixorexton boosts wakefulness in type 1 narcolepsy, shows cognitive and fatigue gains, and hints at ADHD and neurodegenerative uses.

In the first ever episode of "Psychopharm Today," experts unpack why suicide needs its own research, how to design targeted studies, and what clinicians can do beyond diagnosis to reduce risk.

How AI can aid everyday psychiatry—TRD prediction, suicide risk, and smartphone phenotyping—plus why data quality and workflow still block adoption.

Phase 2 depression trial shows ALTO-203 boosts attention, EEG theta-beta ratio and alertness, pointing to biomarker-guided dosing and precision psychiatry.

How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.

Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.

Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.

Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.

AI analyzes wearable data to reveal objective biomarkers for ADHD and anxiety, enabling passive tracking and earlier psychiatric detection.

Expert analysis compares adjunctive atypical antipsychotics for MDD, highlighting lumatperone’s larger effect and minimal weight gain or akathisia.

Yale psychiatrists test esketamine vs IV ketamine for resistant depression, probing long-term safety, side effects, and misuse in real-world care.

APA’s upcoming DSM shifts from “statistical” to “scientific,” adding dimensional, contextual, and biological factors to modernize diagnosis and address past critiques.

After FDA’s new warning, experts stress controlled data show acetaminophen in pregnancy isn’t tied to autism or ADHD; confounding fuels scares.

New evidence shows CBT timed after ketamine boosts lasting depression relief; Yale tests digital therapy Rejoyn to scale the neuroplasticity window.

APA’s next DSM rebrands and adds context, cross-cutting symptoms, and biomarker-ready science to sharpen diagnoses and personalize psychiatric care.

New analysis finds postpartum depression and postpartum psychosis have distinct underlying biological mechanisms.

Weighing the risks and benefits of stimulants to treat ADHD.

Review the origins and advancements of ECT.

Luvesilocin enters phase 2, hinting at lasting relief after 1–2 doses and a new 5-HT2A model.

Phase 2 data suggest luvesilocin quickly eases postpartum depression with durable remission and minimal breast‑milk transfer, supporting larger trials.

S. Nassir Ghaemi, MD, shares highlights from the ASCP task force consensus on psychiatric polypharmacy, emphasizing monotherapy and diagnostic reassessment.

ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.

Patient selection, monitoring, and counseling on dissociation are critical to safe ketamine treatment.

DT-120, an optimized LSD formulation, shows lasting anxiety relief and high remission at 12 weeks, as researchers share detailed phase 2b safety insights.

Phase 2b data show DT‑120, optimized oral LSD, delivers durable GAD remission with mostly same‑day side effects; phase 3 trials advance.

ASCP awardee Leslie Citrome explains why effect size, NNT, and NNH beat P-values, helping clinicians choose treatments tailored to each patient.

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

A phase 2b/3 trial of Forvisirvat in major depressive disorder is investigating potential sex-specific antidepressant effects in women.